SRT-2104
- Generic Name
- SRT-2104
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N6O2S2
- CAS Number
- 1093403-33-8
- Unique Ingredient Identifier
- 4521NR0J09
- Background
SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Sirtris, a GSK Company
- Target Recruit Count
- 17
- Registration Number
- NCT01453491
- Locations
- 🇺🇸
GSK Investigational Site, Jackson, Tennessee, United States
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Sirtris, a GSK Company
- Target Recruit Count
- 40
- Registration Number
- NCT01154101
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01039909
A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Sirtris, a GSK Company
- Target Recruit Count
- 38
- Registration Number
- NCT01031108
- Locations
- 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom
A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT01018017
- Locations
- 🇩🇪
GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany
Effect of SRT2104 on Endotoxin-induced Inflammation
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT01014117
- Locations
- 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00964340
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Sirtris, a GSK Company
- Target Recruit Count
- 227
- Registration Number
- NCT00937326
- Locations
- 🇬🇧
GSK Investigational Site, Newport, United Kingdom
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00933062
- Locations
- 🇬🇧
GSK Investigational Site, Merthyr Tydfill, Glamorgan, United Kingdom
A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers
- Conditions
- Healthy VolunteerDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Sirtris, a GSK Company
- Target Recruit Count
- 43
- Registration Number
- NCT00933530
- Locations
- 🇬🇧
GSK Investigational Site, Merthyr Tydfill, Glamorgan, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.